Read by QxMD icon Read

Cystatin c in acute coronary syndrome

Andrea Driscoll, Elizabeth H Barnes, Stefan Blankenberg, David M Colquhoun, David Hunt, Paul J Nestel, Ralph A Stewart, Malcolm J West, Harvey D White, John Simes, Andrew Tonkin
BACKGROUND: Coronary heart disease is a major cause of heart failure. Availability of risk-prediction models that include both clinical parameters and biomarkers is limited. We aimed to develop such a model for prediction of incident heart failure. METHODS: A multivariable risk-factor model was developed for prediction of first occurrence of heart failure death or hospitalization. A simplified risk score was derived that enabled subjects to be grouped into categories of 5-year risk varying from <5% to >20%...
June 30, 2017: International Journal of Cardiology
Min Liang, Shicheng Yang, Naikuan Fu
BACKGROUND: The prophylactic efficacy of statin pretreatment for the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) remains controversial. The aim of the study was to perform a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness of short-term moderate or high-dose rosuvastatin pretreatment in preventing CIN. METHODS: We included RCTs comparing short-term moderate or high-dose rosuvastatin treatment versus low-dose rosuvastatin treatment or placebo for preventing CIN...
July 2017: Medicine (Baltimore)
Jinjin Zhang, Xianhao Wu, Peizhen Gao, Pingping Yan
BACKGROUND: The aim of this study was to evaluate the predictive value of cystatin C (CysC) and estimated glomerular filtration rate (eGFR) regarding vascular lesions and their severity in patients with acute coronary syndrome (ACS). METHODS: According to the results of coronary angiography, 195 ACS patients were divided into a single-vascular-lesion group (91 cases), a dual-vascular-lesion group (67 cases), and a multiple-vascular-lesion group (37 cases) to assess the severity of coronary artery disease according to Gensini scores and to analyze the correlations of CysC and eGFR level with vascular lesions and severity in ACS patients...
January 31, 2017: BMC Cardiovascular Disorders
Aida Hamzic-Mehmedbasic
INTRODUCTION: Inflammatory markers have been identified as potential indicators of future adverse outcome after acute cardiac events. AIM: This study aimed to analyze baseline inflammatory cytokines levels in patients with acute heart failure (AHF) and/or acute coronary syndrome (ACS) according to survival. The main objective was to identify risk factors for mortality after an episode of AHF and/or ACS. METHODS: In this prospective longitudinal study 75 patients with the diagnosis of AHF and/or ACS were enrolled...
July 27, 2016: Medical Archives
Milos Brankovic, K Martijn Akkerhuis, Nermina Buljubasic, Jin M Cheng, Rohit M Oemrawsingh, Hector M Garcia-Garcia, Evelyn Regar, Patrick W Serruys, Robert-Jan van Geuns, Eric Boersma, Isabella Kardys
BACKGROUND AND AIMS: We investigated whether plasma cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) are associated with intravascular ultrasound (IVUS)-derived characteristics of coronary atherosclerosis and 1-year adverse coronary events in patients with normal and mildly-to-moderately impaired kidney function. METHODS: Between 2008 and 2011, virtual histology (VH)-IVUS of a non-culprit coronary artery was performed in 581 patients undergoing coronary angiography...
November 2016: Atherosclerosis
Isabel Graupera, Elsa Solà, Núria Fabrellas, Rebeca Moreira, Cristina Solé, Patricia Huelin, Gloria de la Prada, Elisa Pose, Xavier Ariza, Alessandro Risso, Sonia Albertos, Manuel Morales-Ruiz, Wladimiro Jiménez, Pere Ginès
UNLABELLED: MCP-1 (monocyte chemoattractant protein-1) is a proinflammatory cytokine involved in chemotaxis of monocytes. In several diseases, such as acute coronary syndromes and heart failure, elevated MCP-1 levels have been associated with poor outcomes. Little is known about MCP-1 in cirrhosis. AIM: To investigate the relationship between MCP-1 and outcome in decompensated cirrhosis. METHODS: Prospective study of 218 patients discharged from hospital after an admission for complications of cirrhosis...
2016: PloS One
Leila Abid, Salma Charfeddine, Samir Kammoun, Mouna Turki, Fatma Ayedi
AIMS: Cystatin C is an endogenous marker of renal function. It is a well established better marker of glomerular filtration rate than serum creatinine. There is also evidence that cystatin C is associated with atherosclerotic disease. The present prospective study evaluated the prognostic value of cystatin C after myocardial infarction in patients without chronic kidney disease. METHODS AND RESULTS: A total of 127 patients who underwent coronary angiography after an acute coronary syndrome (ACS) were included...
July 2016: Journal of the Saudi Heart Association
Pedro J Flores-Blanco, Ángel López-Cuenca, James L Januzzi, Francisco Marín, Marianela Sánchez-Martínez, Miriam Quintana-Giner, Ana I Romero-Aniorte, Mariano Valdés, Sergio Manzano-Fernández
BACKGROUND: Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations estimate glomerular filtration rate (GFR) more accurately than the Modification of Diet in Renal Disease (MDRD) equation. HYPOTHESIS: New CKD-EPI equations improve risk stratification in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and provide complementary information to the Global Registry of Acute Coronary Events (GRACE) risk score. METHODS: We studied 350 subjects (mean age, 68 ± 12 years; 70% male) with NSTE-ACS...
September 2016: Clinical Cardiology
Gaoliang Yan, Wenjie Kong, Dong Wang, Yong Qiao, Xiang Sha, Tianyu Cheng, Hairong Zhang, Jiantong Hou, Chengchun Tang, Genshan Ma
OBJECTIVE: To explore the impact of plasma homocysteinemia(Hcy) on contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients. METHODS: Consecutive 684 ACS patients undergoing first PCI in our department between January 2013 and December 2014 were prospectively enrolled.Patients were divided into 2 groups according to the pre-procedural plasma Hcy level: high-Hcy group (Hcy≥10 μmol/L, n=404) and control group (Hcy<10 μmol/L, n=280)...
January 2016: Zhonghua Xin Xue Guan Bing za Zhi
Emil Hagström, Stefan K James, Maria Bertilsson, Richard C Becker, Anders Himmelmann, Steen Husted, Hugo A Katus, Philippe Gabriel Steg, Robert F Storey, Agneta Siegbahn, Lars Wallentin
AIMS: Growth differentiation factor-15 (GDF-15) predicts death and composite cardiovascular (CV) events in patients with acute coronary syndrome (ACS). We investigated the independent associations between GDF-15 levels and major bleeding, the extent of coronary lesions and individual CV events in patients with ACS. METHODS AND RESULTS: Growth differentiation factor-15 was analysed at baseline ( ITALIC! n = 16 876) in patients with ACS randomized to ticagrelor or clopidogrel in the PLATO (PLATelet inhibition and patient Outcomes) trial...
April 21, 2016: European Heart Journal
Andrew M Tonkin, Stefan Blankenberg, Adrienne Kirby, Tanja Zeller, David M Colquhoun, Anne Funke-Kaiser, Wendy Hague, David Hunt, Anthony C Keech, Paul Nestel, Ralph Stewart, David R Sullivan, Peter L Thompson, Malcolm West, Harvey D White, John Simes
AIMS: In patients with stable coronary heart disease (CHD), we aimed to assess 1. the prognostic power of biomarkers reflecting haemodynamics, micronecrosis, inflammation, coagulation, lipids, neurohumoral activity, and renal function; 2. whether changes in concentrations of these biomarkers over 12 months affected subsequent CHD risk; and 3. whether pravastatin modified the change in biomarker concentrations and this influenced the risk of future events. METHODS: In the LIPID study, 9014 patients were randomised to pravastatin 40 mg or placebo 3-36 months after an acute coronary syndrome...
December 15, 2015: International Journal of Cardiology
Eiryu Sai, Kazunori Shimada, Katsumi Miyauchi, Yoshiyuki Masaki, Takahiko Kojima, Tadashi Miyazaki, Takeshi Kurata, Manabu Ogita, Shuta Tsuboi, Takuma Yoshihara, Tetsuro Miyazaki, Akimichi Ohsaka, Hiroyuki Daida
Chronic kidney disease (CKD) is an important risk factor for coronary artery disease (CAD) and cardiovascular events. Cystatin C (CysC) has been proposed as a sensitive marker for CKD. However, the predictive value of CysC for cardiovascular events in CAD patients with preserved estimated glomerular filtration rate (eGFR) is unclear. We enrolled 277 consecutive patients undergoing elective percutaneous coronary intervention with sirolimus-eluting stents (SES). Patients with an eGFR ≤60 ml/min/1.73 m(2) were excluded...
May 2016: Heart and Vessels
Eduard Shantsila, Luke D Tapp, Gregory Y H Lip
AIMS: We assessed changes of serum combined free immunoglobulin light chains (cFLC) levels, which are associated with increased all-cause mortality, in ST-elevation myocardial infarction (STEMI) in relation to inflammation and renal function indices. METHODS: cFLC were measured in 48 patients with STEMI on days 1, 3, 7 and 30 with assessment of their relationships with monocyte subsets, high sensitivity C-reactive protein (hsCRP), and cystatin C. Day 1 levels in STEMI patients were compared to 40 patients with stable coronary artery disease, and 37 healthy controls...
April 15, 2015: International Journal of Cardiology
Inês Almeida, Francisca Caetano, Sérgio Barra, Marta Madeira, Paula Mota, António Leitão-Marques
AIMS: Renal dysfunction is a powerful predictor of adverse outcomes in patients hospitalized for acute coronary syndrome. Three new glomerular filtration rate (GFR) estimating equations recently emerged, based on serum creatinine (CKD-EPIcreat), serum cystatin C (CKD-EPIcyst) or a combination of both (CKD-EPIcreat/cyst), and they are currently recommended to confirm the presence of renal dysfunction. Our aim was to analyse the predictive value of these new estimated GFR (eGFR) equations regarding mid-term mortality in patients with acute coronary syndrome, and compare them with the traditional Modification of Diet in Renal Disease (MDRD-4) formula...
June 2016: European Heart Journal. Acute Cardiovascular Care
Pedro J Flores-Blanco, Ángel López-Cuenca, James L Januzzi, Francisco Marín, Marianela Sánchez-Martínez, Miriam Quintana-Giner, Ana I Romero-Aniorte, Mariano Valdés, Sergio Manzano-Fernández
BACKGROUND: Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations estimate glomerular filtration rate more accurately than the Modification of Diet in Renal Disease (MDRD) Study equation. Our aim was to evaluate whether CKD-EPI equations based on serum creatinine and/or cystatin C (CysC) predict risk for major bleeding (MB) more accurately than the MDRD Study equation in patients with non-ST-segment elevation acute coronary syndromes (ACS). MATERIALS AND METHODS: Three hundred and fifty consecutive subjects with non-ST-segment elevation ACS (68 ± 12 years, 70% male) were studied...
April 2015: European Journal of Clinical Investigation
Erdal Cavusoglu, Jonathan D Marmur, Sudhanva Hegde, Sunitha Yanamadala, Olcay A Batuman, Vineet Chopra, Gonca Ay, Calvin Eng
OBJECTIVES: To investigate the long-term prognostic significance of baseline plasma MMP-1 levels in a group of well-characterized male patients with known or suspected coronary artery disease, including those presenting with acute coronary syndrome. BACKGROUND: MMP-1 is an interstitial collagenase that is considered the primary enzyme responsible for collagen degradation. In addition, MMP-1 can lead to platelet activation through the PAR1 pathway that is independent of thrombin...
March 2015: Atherosclerosis
Marta Negrusz-Kawecka, Rafał Poręba, Anna Hulok, Krzysztof Sciborski, Jakub Marczak, Tomasz Bańkowski
OBJECTIVES: Cystatin C is a novel marker used in the diagnosis of preclinical chronic kidney disease (CKD). The aim of the study was to assess the role of cystatin C in the diagnosis of coronary artery disease. MATERIAL AND METHODS: The study involved 63 patients of a mean age of 62.7 ± 9.5 years. The population was divided into two groups: Group I were patients with angiographically diagnosed coronary artery disease (CAD) with their first acute coronary syndrome (ACS, n = 45); Group II were patients who had clinically diagnosed coronary disease but were negative on angiography (n = 18)...
July 2014: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Axel Akerblom, Niclas Eriksson, Lars Wallentin, Agneta Siegbahn, Bryan J Barratt, Richard C Becker, Andrzej Budaj, Anders Himmelmann, Steen Husted, Robert F Storey, Asa Johansson, Stefan K James
PURPOSE: Elevated cystatin C concentration is an independent risk factor for cardiovascular (CV) events in patients with acute coronary syndromes. Genetic polymorphisms in CST3 influence cystatin C levels, but their relationship to outcomes is unclear. METHODS: We measured cystatin C concentrations in plasma, obtained within 24 hours of admission, in 16,279 acute coronary syndrome patients from the PLATO trial. In 9,978 patients, we performed a genome-wide association study with up to 2...
July 2014: American Heart Journal
Yuqi Liu, Lei Gao, Qiao Xue, Muyang Yan, Pu Chen, Yu Wang, Yang Li
BACKGROUND: This study investigated the impact of renal dysfunction (RD) on long-term outcomes in elderly patients with acute coronary syndrome (ACS), and evaluated prognostic factors in elderly patients with ACS and RD. METHODS: This longitudinal prospective study included 184 consecutive patients who were admitted with ACS between January 2009 and January 2010 and also had RD. Patients were divided into five groups according to their estimated glomerular filtration rate (eGFR): 1) eGFR ≥ 90 mL/min/1...
May 9, 2014: BMC Nephrology
Pablo Piñón, Juan Carlos Kaski
It is well-known that inflammation plays a role in atherogenesis, atherosclerotic plaque progression, and acute coronary syndrome. Inflammatory cells, and cytokines and other biomolecules are implicated in these processes, and have, therefore, been investigated as potential markers of atherosclerotic plaque progression and cardiovascular disease risk. The best characterized and most widely studied is C-reactive protein. However, its role in the clinical setting is still debated. Emerging novel biomarkers that may provide information complementary to that derived from C-reactive protein include pregnancy-associated plasma protein A, lipoprotein-associated phospholipase A2, and cystatin C...
March 2006: Revista Española de Cardiología
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"